Hartaj Singh
Stock Analyst at Oppenheimer
(1.77)
# 3,349
Out of 5,141 analysts
106
Total ratings
47.37%
Success rate
-6.48%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $18.88 | +95.97% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $779.67 | +15.43% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $151.40 | -17.44% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $476.90 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $49.72 | - | 6 | Dec 11, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $473.42 | +26.74% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $49.87 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $3.90 | +156.41% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.32 | +4,445.45% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.94 | +363.92% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.73 | +2,212.14% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $11.29 | +94.86% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.04 | - | 4 | Jul 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $4.15 | +15,562.65% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $15.94 | +88.21% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $18.88
Upside: +95.97%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $779.67
Upside: +15.43%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $151.40
Upside: -17.44%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $476.90
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $49.72
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $473.42
Upside: +26.74%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $49.87
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $3.90
Upside: +156.41%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.32
Upside: +4,445.45%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.94
Upside: +363.92%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.73
Upside: +2,212.14%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $11.29
Upside: +94.86%
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.04
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $4.15
Upside: +15,562.65%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $15.94
Upside: +88.21%